Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Cytokinetics (CYTK) Equity Average (2016 - 2025)

Cytokinetics (CYTK) has disclosed Equity Average for 14 consecutive years, with -$590.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Equity Average changed N/A to -$590.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$590.4 million, a N/A change, with the full-year FY2023 number at -$247.1 million, down 463.5% from a year prior.
  • Equity Average was -$590.4 million for Q4 2025 at Cytokinetics, down from -$444.9 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $246.4 million in Q4 2021 to a low of -$590.4 million in Q4 2025.
  • A 5-year average of -$128.3 million and a median of -$140.2 million in 2025 define the central range for Equity Average.
  • Peak YoY movement for Equity Average: skyrocketed 419.92% in 2021, then crashed 1040.25% in 2025.
  • Cytokinetics' Equity Average stood at $246.4 million in 2021, then plummeted by 125.13% to -$61.9 million in 2022, then plummeted by 566.08% to -$412.6 million in 2023, then surged by 111.47% to $47.3 million in 2024, then plummeted by 1347.63% to -$590.4 million in 2025.
  • Per Business Quant, the three most recent readings for CYTK's Equity Average are -$590.4 million (Q4 2025), -$444.9 million (Q3 2025), and -$317.6 million (Q2 2025).